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ABSTRACT
Age-differential association between serum uric 
acid and incident hypertension
Seung Won Lee
Department of Public Health
The Graduate School of Yonsei University
(Directed by Professor Hyeon Chang Kim, MD, PhD)
Introduction:
Increasing evidence suggests that elevated serum uric acid level is associated with an
increased risk of hypertension. Although the positive association between serum uric acid 
vand incident hypertension has been reported in many previous studies, this association is 
inconsistent according to age, sex, lipid profiles and adiposity level. Additionally, data on 
interaction of serum uric acid and other risk factors on incident hypertension in general 
Korean population are limited. Thus, we aimed to investigate whether there is an
independent association between serum uric acid and the risk of hypertension in Korean 
population, and to assess the interaction between serum uric acid and other risk factors on 
the risk of developing hypertension.
Methods:
This prospective cohort study included 808 participants aged 40-79 years from the 
Korean Genome Epidemiology Study (KoGES), which is an ongoing rural community-
based cohort study. They were free of hypertension and major cardiovascular disease at 
baseline. Hypertension was defined as systolic blood pressure ≥ 140 mmHg, diastolic 
blood pressure ≥ 90 mmHg, or using antihypertensive medication. Serial multivariable 
linear regression models were used to investigate cross-sectional association between 
serum uric acid and blood pressure. Covariates were sex, age, body mass index, high-
density lipoprotein cholesterol and creatinine. A generalized linear model was used to 
estimate the relative risks for incident hypertension according to serum uric acid level at 
baseline. In addition to, to examine the consistency of the observed association between 
serum uric acid and hypertension, we performed subgroup analyses of participants 
according to sex, age (< 55, ≥ 55 years), body mass index (< 25, ≥ 25 kg/m2), 
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triglycerides (< 150, ≥ 150 mg/dL), high-density lipoprotein cholesterol (40 ≤, > 40 
mg/dL), low-density lipoprotein cholesterol (130 ≤, > 130 mg/dL) and fasting glucose 
(100 ≤, > 100 mg/dL) levels. The p value for interactions between serum uric acid and 
other risk factors for incident hypertension were calculated using a Z-test.
Results:
In this study, 314 male and 494 female which is middle-aged adults were included.
During the mean follow-up of 3.3 years, cases of incident hypertension were 36 (11.5%) 
in men and 53 (10.7%) in women. In a cross-sectional analysis, serum uric acid level was
positively associated with diastolic blood pressure when adjusting for sex, age, body mass 
index, high-density lipoprotein cholesterol and creatinine only in men. In a longitudinal 
analysis, the association between serum uric acid and incident hypertension was different
by participant’s age (p for interaction=0.009). There was no significant association 
between serum uric acid and incident hypertension in participants of age ≥ 55 years, but 
we found a significant association between serum uric acid and incident hypertension in 
participants of age < 55 years (relative risk 1.74 per 1.0 mg/dL increase in serum uric acid, 
p=0.002). However, BMI, triglycerides, fasting glucose, high-density lipoprotein and 
low-density lipoprotein cholesterol did not affect the association between serum uric acid 
and incident hypertension. 
Conclusion:
vii
We observed that age-differential association between serum uric acid level and 
incident hypertension among community-dwelling healthy Korean population. Among
people who aged < 55 years, increased serum uric acid level was associated with 
increased risk of developing hypertension. It is recommended to measure and control 
serum uric acid level for middle-aged population to identify high-risk individuals and 
prevent future hypertension.
Keywords: hypertension, blood pressure, uric acid, interaction, risk factor, age
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I. Introduction
Hypertension, the most important modifiable risk factor1,2, is the leading cause of 
death and a major health burden in the worldwide3,4. Hypertension is a common disease 
among Korean elderly population aged 65 years or older considering that its prevalence 
2increased between 2007 and 2011 from 49.3% to 58.4% in men and from 61.8% to 68.9% 
in women5. Previous studies have been reported that the reduction of highly or 
moderately elevated blood pressure levels results in a decrease in stroke and myocardial 
infarction rates6,7. To decrease the rates of mortality and cardiovascular disease effectively, 
it is important to prevent incident hypertension. It is also important to understand the 
interrelationships of various risk factors for hypertension to prevent development of 
hypertension and cardiovascular disease.
Serum uric acid is the metabolic end product of purines in humans and increased 
serum uric acid levels are known to be associated with an increased risk of hypertension8-
11. Serum uric acid has been found to be positively related not only to the risk of 
hypertension but also to the risk of atherosclerosis, cardiovascular diseases and metabolic 
syndrome12-14. Previous studies have reported that blood pressure is lowered by uric acid-
lowering drugs15,16. The positive association between uric acid and blood pressure has 
been reported, suggesting that linking mechanism between hyperuricemia and 
hypertension is renal and metabolic abnormalities17-19. Hyperuricemia can also cause 
systemic inflammation20 and insulin resistance21,22. 
Although the positive association between serum uric acid and incident hypertension
has been reported in many previous studies, this association is inconsistent according to 
age, sex, lipid profiles and adiposity level. In addition to, there are insufficient data on 
interaction of serum uric acid and other factors on incident hypertension in general 
Korean population. Thus, we investigated whether there is independent association
3between serum uric acid and incident hypertension among general Korean population, 
and whether the association is modified by other risk factors of incident hypertension.
4II. Materials and Methods
1. Study population
This study analyzed data from the Korean Genome Epidemiology Study (KoGES)-
Kangwha Study which is a rural community-based prospective cohort23. A total of 4,900
people aged more than 40 years were enrolled between 2006 and 2011. The participants 
were all independently living in from Kangwha Island, Incheon, South Korea. 
For this study, we analyzed baseline and the follow-up data of eligible participants 
(n=4,210) who had information for serum uric acid levels between 2008 and 2013. We 
excluded individuals who had a history of stroke, angina pectoris or myocardial infarction 
at baseline (n=178). We also excluded individuals with high blood pressure (systolic 
blood pressure ≥ 140; diastolic blood pressure 90 mmHg (n=458)) and/or taking 
antihypertensive drugs (n=655) at baseline. After further excluding individuals who had 
no measurement of uric acid (n=1,192) or missing key covariates (n=1) or outlier (n=11), 
the final sample was 808 individuals (314 men and 494 women) who were aged 55.4
years. 
All participants provided written informed consent form and study protocol was 
approved by the Institutional Review Board of Yonsei University Graduate School of 
Public Health (2-1040939-AB-N-01-2016-403).
5Figure 1. Flow chart of the selection criteria for the final study population
62. Measurements
A. Questionnaire data
All participants had an individual interview using standardized questionnaires to 
obtain information about their demographics, medical history, and health-related lifestyle. 
All interviewers were trained and performed questionnaire surveys according to a 
prescribed procedure. Smoking status was categorized as current smoking group and 
current nonsmoking group (ex-smokers and non-smokers). Alcohol intake was also 
classified into two groups: current alcohol drinking or current nondrinking (past alcohol 
drinking and never drinking). 
B. Anthropometrics
Participants were required to refrain from smoking or ingesting caffeine for eight 
hours preceding the health examination. Prior to blood pressure measurements,
participants were asked to sit and rest in a room for at least five minutes. With 
participants seated, an appropriately sized cuff was applied snugly around the upper right 
arm at the heart level. Cuff size was chosen for each subject according to mid-arm 
circumference. Heart rate and blood pressure were measured twice with at least a 5-
minute interval between measurements using an automatic sphygmomanometer 
(Dinamap 1846 SX/P; GE Healthcare, USA). If the difference between the first and 
second measurements was greater than 10 mmHg, additional measurements were taken. 
The average of the last two measurements was used for analysis. Hypertension was 
7defined as average systolic blood pressure ≥ 140mmHg or average diastolic blood 
pressure ≥ 90mmHg or current blood pressure medication use. Standing height was 
measured to the nearest 0.1 cm on a stadiometer (SECA763, SECA GMBH, Germany). 
Body weight was measured to the nearest 0.1 kg on a digital scale (GL-60000-20, Seoul, 
Korea) with participants wearing underwear and examination gowns. Body mass index 
(BMI) was calculated as an individual’s body weight in kilograms divided by their height 
in meters squared (Kg/m2).
C. Laboratory assays
After at least eight hours of fast, blood samples were collected from the antecubital 
vein in the morning. Fasting blood glucose levels were determined by a colorimetry 
method (ADVIA 1800; Siemens Medical Solutions), and fasting insulin levels were 
determined by a immunoradiometric assay (SR-300; Stratec, Birkenfeld, Germany).
Homeostasis model assessment of insulin resistance (HOMA-IR) was used to evaluate 
insulin resistance: HOMA-IR = fasting glucose (mg/dL) × fasting insulin (μIU/mL)/40524. 
Enzymatic methods were used to measure total cholesterol, high-density cholesterol 
(HDL), triglyceride and total protein levels (ADVIA 1800; Siemens Medical Solutions, 
Pleasanton, CA, USA). Low-density-lipoprotein (LDL) cholesterol levels were calculated 
using the Friedewald formula25. Blood urea creatinine was measured by colorimetric 
methods using automatic analyzers (ADVIA 1650, Bayer Corp, USA). The glomerular 
filtration rate (GFR) was calculated by Cockcroft and Gault formula26. C-reactive protein 
8(CRP) was measured by turbidimetric immunoassay assay (ADVIA 1800; DenKa Seiken, 
Japan).
D. Statistical analysis
Gender differences of general characteristics were analyzed using the independent t-
test and the Wilcoxon rank-sum test for continuous variables, and the chi-square test for 
categorical variables. Fasting glucose level, insulin, triglycerides and CRP were log-
transformed for parametric testing due to the right-skewed distribution. The relationships 
between serum uric acid and other variables at baseline were evaluated using Pearson’s 
correlation analysis. We also evaluated linear trend and presented p for trend according to 
quartile range of serum uric acid at baseline which was a major interesting variable. We 
used a contrast to test for linear trends to calculate p values for continuous variables. We 
also used the Cochran-Armitage test to examine the existence of a linear trend of 
categorical variables. We made a comparison between baseline characteristics of people 
who developed hypertension and those who did not. Differences in continuous variable 
and normally distributed variables were tested by independent t-test and Wilcoxon rank 
sum test, respectively. Categorical variables were described as numbers with percentage
and tested by chi-square tests or Fisher's exact test (for categorical variables with small 
expected numbers).
To access the cross-sectional associations between serum uric acid and blood pressure, 
we used serial multivariable linear regression model: model 1 was adjusted for sex (only 
9in pooled analysis) and age; model 2 was additionally adjusted for BMI; and model 3 was 
additionally adjusted for HDL cholesterol and creatinine. Potential confounders were 
evaluated by backward selection method and previous study results. We also presented 
penalized B-splines to explore the patterns of association between serum uric acid and 
blood pressure at baseline. Penalized regression methods were used that use a suitable
penalty functional to quantify the notion of roughness of a curve, with a necessary 
compromise between bias and variability in curve fitting27.
A relative risks of hypertension during follow-up period and associated 95% 
confidence intervals according to serum uric acid levels were estimated by generalized 
linear models with log-link-function and a Poisson distribution using robust variance 
estimator28,29. This was done the proportion of the outcome was greater than 10% in 
which case odd ratios would provide biased estimates of associations30. In addition to,
restricted cubic spline was used to investigate the possibility of non-linearity association 
between serum uric acid and incident hypertension31. In this method, we selected five 
serum uric acid values as knots based on serum uric acid percentiles, tested the linear and 
non-linear associations between knots using a cubic function, and presented the integrated 
graph smoothly. Since the restricted cubic spline could be affected by outliers, we 
excluded values lower than the 1st percentile and greater than the 99th percentile. To 
examine the consistency of the observed association between serum uric acid and 
hypertension, we performed subgroup analyses of participants according to age (< 55, ≥
55 years), BMI (< 25, ≥ 25 kg/m2), triglycerides (< 150, ≥ 150 mg/dL), HDL cholesterol
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(40 ≤, > 40 mg/dL) and LDL cholesterol (130 ≤, > 130 mg/dL) which are known risk 
factors for incident hypertension. The p value for interactions between serum uric acid 
and other risk factors on the incident hypertension were calculated by a Z-test. All 
analyses were performed using SAS statistical software, version 9.4 (SAS Institute Inc., 
Cary, NC, USA), and statistical significance was defined as a two-sided p value of < 0.05.
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III. Results
Baseline characteristics of study population are presented in Table 1. The mean age of 
the study population was 57.1years in 314 men and 54.3 years in 494 women. The mean 
level of serum uric acid was 5.7 mg/dL in men and 4.4 mg/dL in women. Age, SBP, DBP, 
fasting glucose, triglycerides, creatinine, GFR, serum uric acid, smoking and alcohol 
intake were significantly higher in men than in women. However, fasting insulin level, 
total cholesterol, HDL cholesterol and LDL cholesterol were higher in women than in 
men. During follow-up period (mean 3.3 years), 36 men (11.5%) and 53 women (10.7%) 
developed hypertension.
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Table 1. General characteristics of study population 
Variables Total (n=808) Men (n=314) Women (n=494) p value
Age, year 55.4 ± 7.2 57.1 ± 6.9 54.3 ± 7.3 <.001
BMI, kg/m2 24.5 ± 3.1 24.2 ± 2.9 24.6 ± 3.2 0.089 
SBP, mmHg 116.1 ± 12.2 117.2 ± 11.6 115.4 ± 12.6 0.035 
DBP, mmHg 72.0 ± 8.3 74.7 ± 7.8 70.3 ± 8.2 <.001
Fasting glucose, mg/dL 91.0 [86-98] 93.0 [87-102] 90.0 [85-97] <.001
Fasting insulin, mg/dL 7.7 [6.0-10.2] 7.0 [5.7-9.8] 8.0 [6.2-10.5] <.001
HOMA-IR 2.0 ± 1.0 2.0 ± 1.0 2.0 ± 1.0 0.396 
Total cholesterol, mg/dL 195.6 ± 34.5 189.1 ± 33.3 199.6 ± 34.6 <.001
HDL cholesterol, mg/dL 45.5 ± 10.8 43.7 ± 10.3 46.6 ± 11.0 <.001
LDL cholesterol, mg/dL 121.7 ± 32.5 115.2 ± 31.9 125.9 ± 32.2 <.001
Triglycerides, mg/dL 122.5 [86-171] 135.5 [92-187] 114.0 [84-163] 0.001 
Creatinine, mg/dL 0.9 ± 0.2 1.0 ± 0.1 0.9 ± 0.1 <.001
GFR, mL/min/1.73m2 69.8 ± 14.9 72.4 ± 15.1 68.1 ± 14.5 <.001
Uric acid, mg/dL 4.9 ± 1.3 5.7 ± 1.3 4.4 ± 1.0 <.001
CRP, mg/L 0.6 [0.3-1.3] 0.7 [0.4-1.3] 0.6 [0.3-1.4] 0.406 
Current smoker (n=778) 81 (10.4) 75 (24.8) 6 (1.3) <.001
Current drinker (n=806) 310 (38.5) 184 (58.6) 126 (25.6) <.001
Incident hypertension 89 (11.0) 36 (11.5) 53 (10.7) 0.833 
Values are presented as mean ± standard deviation, median [interquartile range], or number (%).
P value was derived from the independent t-test, the Wilcoxon rank sum test, or chi-square test.
Abbreviation: BMI, body mass index; CRP, C-reactive protein; DBP, diastolic blood pressure; GFR, 
glomerular filtration ratio; HDL, high-density lipoprotein; HOMA-IR, homeostatic model assessment 
for insulin resistance; LDL, low-density lipoprotein; SBP, systolic blood pressure
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Table 2 shows the baseline characteristics and incident hypertension of study 
population according to the categories of baseline uric acid levels in quartiles. Men with 
higher serum uric acid level had significantly higher levels of BMI, fasting insulin, 
HOMA-IR, creatinine, CRP and triglycerides at baseline. Men with higher blood pressure 
also had a higher proportion of current drinker. However, men with higher serum uric 
acid level had significantly lower levels of LDL cholesterol. The cases of incident 
hypertension during the follow-up period were 7 cases (9.9 %) for the first quartile, 7 
cases (8.8 %) for the second quartile, 8 cases (9.9 %) for the third quartile and 17 cases 
(17.1 %) for the fourth quartile of serum uric acid in men.
On the other hand, women who had a higher level of serum uric acid had significantly 
older ages and higher levels of BMI, fasting insulin, HOMA-IR, triglycerides, creatinine 
and CRP. However, women with higher serum uric acid level had significantly lower 
levels of HDL cholesterol and GFR. The cases of incident hypertension during the 
follow-up period were 8 cases (6.5%) for the first quartile, 13 cases (10.6%) for the 
second quartile, 19 cases (15.7%) for the third quartile and 13 cases (10.2%) for the 
fourth quartile of serum uric acid in women.
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Table 2. Characteristics of study participants according to serum uric acid level in quartiles
Serum uric acid level at baseline
p-trend
Q1 Q2 Q3 Q4
Men (n=314) (n=71) (n=80) (n=81) (n=82)
Uric acid, mg/dL 4.2 ± 0.6 5.3 ± 0.2 6.0 ± 0.3 7.3 ± 0.9 <.001
Age, years 58.2 ± 6.6 57.4 ± 7.0 56.5 ± 6.3 56.6 ± 7.5 0.109
BMI, kg/m2 23.8 ± 3.2 24.0 ± 2.8 24.4 ± 2.9 24.8 ± 2.9 0.017
SBP, mmHg 116.6 ± 12.3 118.6 ± 11.4 115.3 ± 12.0 118.4 ± 10.9 0.739
DBP, mmHg 73.8 ± 8.6 74.3 ± 7.8 74.9 ± 7.6 75.9 ± 7.1 0.081
Fasting glucose, mg/dL 91.0 [87-105] 93.5 [87-101] 94.0 [87-100] 94.0 [87-102] 0.685
Fasting insulin, mg/dL 6.8 [5.0-9.8] 6.8 [5.5-9.0] 6.9 [6.0-9.8] 8.1 [6.1-10.5] 0.012
HOMA-IR 1.8 ± 0.9 1.8 ± 0.9 2.0 ± 1.1 2.1 ± 1.0 0.045
Total cholesterol, mg/dL 193.3 ± 29.6 184.8 ± 32.7 192.0 ± 37.6 186.9 ± 32.4 0.506
HDL cholesterol,mg/dL 45.3 ± 9.9 44.3 ± 12.1 43.2 ± 9.1 42.3 ± 9.8 0.062
LDL cholesterol,mg/dL 122.2 ± 30.2 112.4 ± 29.3 119.1 ± 34.8 108.1 ± 31.6 0.031
Triglycerides, mg/dL 104.0 [74-156] 126.0 [82-177] 130.0 [94-189] 161.5 [94-189] 0.770
Creatinine, mg/dL 1.0 ± 0.1 1.0 ± 0.1 1.0 ± 0.1 1.1 ± 0.2 <.001
GFR, mL/min/1.73m2 74.9 ± 14.8 75.9 ± 17.4 75.9 ± 15.2 73.0 ± 14.3 0.456
CRP, mg/L 0.5 [0.3-1.0] 0.6 [0.4-1.1] 0.7 [0.4-1.2] 0.8 [0.4-1.2] <.001
Smoking (n=303) 15 (23.1) 18 (23.4) 20 (25.3) 22 (26.8) 0.550*
Alcohol intake 30 (42.3) 46 (57.5) 53 (65.4) 55 (67.1) 0.001*
Incident hypertension 7 (9.9) 7 (8.8) 8 (9.9) 14 (17.1) 0.147
Women (n=494) (n=123) (n=123) (n=121) (n=127)
Uric acid, mg/dL 3.3 ± 0.4 4.0 ± 0.2 4.7 ± 0.2 5.7 ± 0.7 <.001
Age, years 53.3 ± 7.4 53.3 ± 6.8 55.6 ± 6.7 55.3 ± 7.9 0.005
BMI, kg/m2 23.7 ± 3.0 24.9 ± 3.1 24.5 ± 3.1 25.5 ± 3.3 <.001
SBP, mmHg 115.3 ± 13.5 113.9 ± 12.7 116.2 ± 11.7 116.1 ± 12.4 0.353
DBP, mmHg 69.5 ± 8.4 69.5 ± 8.6 70.7 ± 8.1 71.2 ± 7.8 0.062
Fasting glucose, mg/dL 88.0 [83-92] 91.0 [86-96] 91.0 [85-98] 92.0 [87-98] 0.061
Fasting insulin, mg/dL 7.4 [5.8-9.7] 7.5 [6.1-10.0] 8.6 [6.2-10.9] 9.0 [7.0-11.0] <.001
HOMA-IR 1.7 ± 0.8 1.9 ± 0.7 2.2 ± 1.3 2.2 ± 0.9 <.001
Total cholesterol, mg/dL 195.1 ± 34.3 199.2 ± 33.0 201.8 ± 34.6 202.5 ± 36.3 0.077
HDL cholesterol,mg/dL 48.2 ± 11.8 46.5 ± 11.4 47.6 ± 10.3 44.2 ± 9.9 0.012
LDL cholesterol,mg/dL 124.1 ± 30.8 128.6 ± 30.6 125.9 ± 32.3 124.9 ± 35.1 0.968
Triglycerides, mg/dL 94.0 [74-136] 108.0 [86-145] 118.0 [86-171] 139.0 [96-206] <.001
Creatinine, mg/dL 0.8 ± 0.1 0.8 ± 0.1 0.8 ± 0.1 0.9 ± 0.1 <.001
GFR, mL/min/1.73m2 71.9 ± 14.0 72.8 ± 13.2 69.0 ± 16.5 67.7 ± 15.6 0.006
CRP, mg/L 0.5 [0.2-0.9] 0.5 [0.3-1.1] 0.7 [0.3-1.5] 1.1 [0.4-2.1] <.001
Smoking (n=476) 1 (0.9) 1 (0.8) 2 (1.7) 2 (1.7) 0.466*
Alcohol intake (n=484) 36 (29.5) 29 (23.8) 28 (23.1) 33 (26.0) 0.532*
Incident hypertension 8 (6.5) 13 (10.6) 19 (15.7) 13 (10.2) 0.197
Data was expressed as mean ± standard deviation or number (percent).
*P-trend was derived from the Cochran-Armitage trend test.
Abbreviation: BMI, body mass index; CRP, C-reactive protein; DBP, diastolic blood pressure; GFR, glomerular filtration ratio; 
HDL, high-density lipoprotein; HOMA-IR, homeostatic model assessment for insulin resistance; LDL, low-density lipoprotein; 
SBP, systolic blood pressure
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Table 3 presents the correlations between serum uric acid and other variables using 
the Pearson’s correlation coefficient. In men, serum uric acid had positive correlations 
with BMI, SBP, fasting glucose, HDL cholesterol, creatinine, GFR and CRP in age-
adjusted model. On the other hand, serum uric acid had negative correlations HOMA-IR, 
total cholesterol and LDL cholesterol in men. 
In women, serum uric acid had positive correlations with BMI, fasting glucose, HDL 
cholesterol, creatinine, GFR and CRP in age-adjusted model. On the other hand, serum 
uric acid had a negative correlation with HOMA-IR in women. The correlations between 
blood pressure and other characteristics in baseline were presented in Table A1.
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Table 3. Correlation between serum uric acid level and other characteristics in baseline 
Simple correlation* Partial correlation†
Pearson's 
coefficients
p-value
Pearson's 
coefficients
p-value
Total (n=808)
Age 0.04 0.207 NA NA
BMI 0.18 <.001 0.18 <.001
SBP 0.10 0.006 0.10 0.005 
DBP 0.03 0.350 0.02 0.488 
Fasting glucose (logarithmic) 0.16 <.001 0.16 <.001
Fasting Insulin (logarithmic) 0.04 0.313 0.04 0.304 
HOMA-IR - 0.12 0.001 - 0.12 0.001 
Total cholesterol - 0.05 0.130 - 0.05 0.137 
HDL cholesterol 0.37 <.001 0.37 <.001
LDL cholesterol - 0.10 0.005 - 0.09 0.011 
Triglycerides (logarithmic) 0.02 0.590 0.02 0.607 
Creatinine 0.19 <.001 0.19 <.001
GFR 0.28 <.001 0.28 <.001
CRP (logarithmic) 0.21 <.001 0.21 <.001
Men (n=314)
Age - 0.07 0.211 NA NA
BMI 0.17 0.002 0.16 0.004 
SBP 0.15 0.008 0.14 0.014 
DBP 0.02 0.716 0.03 0.619 
Fasting glucose (logarithmic) 0.15 0.008 0.14 0.013 
Fasting Insulin (logarithmic) - 0.03 0.582 - 0.04 0.484 
HOMA-IR - 0.12 0.037 - 0.12 0.040 
Total cholesterol - 0.13 0.026 - 0.13 0.021 
HDL cholesterol 0.33 <.001 0.33 <.001
LDL cholesterol - 0.05 0.338 - 0.12 0.033 
Triglycerides (logarithmic) - 0.05 0.358 - 0.06 0.284 
Creatinine 0.20 <.001 0.19 0.001 
GFR 0.29 <.001 0.28 <.001
CRP (logarithmic) 0.11 0.052 0.12 0.040 
Women (n=494)
Age 0.13 0.004 NA NA
BMI 0.19 <.001 0.19 <.001
SBP 0.06 0.199 0.05 0.238 
DBP 0.04 0.344 0.01 0.837 
Fasting glucose (logarithmic) 0.16 <.001 0.15 0.001 
Fasting Insulin (logarithmic) 0.09 0.053 0.08 0.068 
HOMA-IR - 0.13 0.005 - 0.12 0.009 
Total cholesterol <.01 0.958 <.01 0.965 
HDL cholesterol 0.41 <.001 0.40 <.001
LDL cholesterol - 0.14 0.002 - 0.08 0.075 
Triglycerides (logarithmic) 0.09 0.059 0.07 0.116 
Creatinine 0.18 <.001 0.18 <.001
GFR 0.28 <.001 0.26 <.001
CRP (logarithmic) 0.29 <.001 0.27 <.001
*Adjusted for sex; †Adjusted for sex and age 
Abbreviation: BMI, body mass index; CRP, C-reactive protein; DBP, diastolic blood pressure; GFR, glomerular 
filtration ratio; HDL, high-density lipoprotein; HOMA-IR, homeostatic model assessment for insulin resistance; 
LDL, low-density lipoprotein; SBP, systolic blood pressure
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Table 4 presents baseline characteristics of the study population according to the 
incident hypertension during follow-up period. In men, BMI, SBP, DBP, fasting insulin 
and triglycerides were significantly higher in those who developed hypertension than in 
those who did not. In women, age, BMI, SBP and DBP were significantly higher in those 
who developed hypertension than in those who did not. On the contrary, HDL cholesterol 
was significantly lower in those who developed hypertension than in those who did not in 
women. Total cholesterol was higher in those who developed hypertension compared with 
those who did not, but the association was of borderline significance. In both sexes, 
serum uric acid level was higher in those who developed hypertension compared with 
those who did not, but the difference between these groups was not statistically 
significant.
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Table 4. Baseline characteristics of study participants according to incident hypertension during the follow-up period
Men (n=314) Women (n=494)
Variables
Non-hypertension at f/u 
(n=278)
Hypertension at f/u
(n=36)
p-value
Non-hypertension at f/u 
(n=441)
Hypertension at f/u
(n=53)
p-value
Age, years 57.0 ± 6.9 58.4 ± 6.9 0.243 54.0 ± 7.2 57.5 ± 7.5 0.001 
BMI, kg/m2 24.1 ± 3.0 25.6 ± 2.3 0.003 24.5 ± 3.1 25.6 ± 3.5 0.015 
SBP, mmHg 116.4 ± 11.7 123.4 ± 8.8 <.001 114.1 ± 12.4 125.9 ± 9.1 <.001
DBP, mmHg 74.3 ± 7.8 77.9 ± 6.6 0.010 69.6 ± 8.1 75.7 ± 7.2 <.001
HOMA-IR 1.9 ± 1.0 2.1 ± 0.7 0.243 2.0 ± 0.9 2.2 ± 1.5 0.402 
Fasting glucose, mg/dL 93.0 [87.0-101.0] 95.5 [90.0-105.0] 0.202 90.0 [85.0-96.0] 8.0 [85.0-97.0] 0.944 
Fasting insulin, mg/dL 6.9 [5.4-9.8] 8.0 [7.0-10.25] 0.018 8.0 [6.3-10.5] 7.9 [6.2-10.7] 0.922 
Total cholesterol, mg/dL 189.9 ± 33.4 183.0 ± 32.7 0.239 200.3 ± 34.5 194.4 ± 34.9 0.244 
HDL cholesterol,mg/dL 44.0 ± 10.3 41.8 ± 10.0 0.231 46.9 ± 10.8 43.9 ± 12.3 0.056 
LDL cholesterol,mg/dL 116.1 ± 32.4 108.8 ± 27.0 0.198 126.4 ± 32.1 121.9 ± 33.5 0.047 
Uric acid, mg/dL 5.7 ± 1.2 6.1 ± 1.5 0.181 4.4 ± 1.0 4.7 ± 1.2 0.332 
Triglycerides, mg/dL 130.0 [89.0-188.0] 157.5 [132.5-187.0] 0.044 113.0 [84.0-162.0] 113.0 [88.0-175.0] 0.250 
Creatinine, mg/dL 1.0 ± 0.1 1.0 ± 0.1 0.955 0.9 ± 0.1 0.8 ± 0.1 0.844 
GFR, mL/min/1.73m2 74.5 ± 15.2 78.0 ± 16.7 0.198 70.5 ± 15.0 69.1 ± 14.7 0.513 
CRP, mg/L 0.6 [0.4-1.3] 0.7 [0.4-1.3] 0.574 0.6 [0.3-1.4] 0.8 [0.4-1.6] 0.190 
Current smoker 65 (24.3) 10 (28.6) 0.728 6 (1.4) 0 (0.0) 0.838 
Current drinker 161 (57.9) 23 (63.9) 0.614 118 (26.9) 8 (15.1) 0.090 
p-value was derived from the independent t-test, the Wilcoxon rank sum test, chi-square test or Fisher's exact test.
Abbreviation: BMI, body mass index; CRP, C-reactive protein; DBP, diastolic blood pressure; GFR, glomerular filtration ratio; HDL, high-density 
lipoprotein; HOMA-IR, homeostatic model assessment for insulin resistance; LDL, low-density lipoprotein; SBP, systolic blood pressure
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Tables 5 present a cross-sectional association between serum uric acid and blood 
pressure at baseline using multivariable linear regression model. 
Serum uric acid was not associated with SBP before and after adjusting for covariates
in both sexes. But serum uric acid was positively associated with DBP in men before and 
after adjusting for age, BMI, HDL cholesterol and creatinine (β = 0.85, p = 0.014 for 
unadjusted model; β = 0.86, p = 0.017 for fully adjusted model).
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Table 5. Cross-sectional association between serum uric acid level and blood pressure at 
baseline by multivariable linear regression model
Association between serum uric 
acid (mg/dL) and SBP (mmHg)
Association between serum uric 
acid (mg/dL) and DBP (mmHg)
β R2 p value β R2 p value
Total (n=808)
Model 1 0.27 0.043 0.488 0.71 0.076 0.005
Model 2 - 0.11 0.076 0.774 0.49 0.100 0.057 
Model 3 0.13 0.077 0.754 0.58 0.100 0.035
Men (n=314)
Model 1 0.26 0.005 0.619 0.85 0.044 0.014
Model 2 - 0.09 0.056 0.858 0.68 0.069 0.049
Model 3 0.31 0.068 0.565 0.86 0.074 0.017
Women (n=494)
Model 1 0.11 0.062 0.837 0.44 <.001 0.238
Model 2 - 0.25 0.083 0.659 0.19 0.023 0.605
Model 3 - 0.21 0.081 0.733 0.15 0.019 0.710
Model 1: adjusted for sex and age
Model 2: adjusted for sex, age and BMI
Model 3: adjusted for sex, age, BMI, HDL cholesterol and creatinine
Abbreviation: BMI, body mass index; DBP, diastolic blood pressure; HDL, high-density 
lipoprotein; SBP, systolic blood pressure
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Figures 2-5 present penalized B-splines to explore the patterns of the association between 
serum uric acid and blood pressure by sex. Solid lines, gray shadows and blue dash lines
represent the estimated blood pressure, 95% confidence intervals and 95% prediction 
intervals according to serum uric acid level. The estimated blood pressure was calculated 
by using the penalized regression method. The 95% confidence interval means that the 
possibility of blood pressure lying within these bands (shades) is 95%, while the 95% 
prediction interval means that the possibility of a specific observation lying within these 
bands (dashed lines) is 95% when we are interested in a specific observation (i.e. 
independent variable: serum uric acid). In men, serum uric acid level shows a linear 
association with DBP. However, in women, there was no significant association between 
serum uric acid level and DBP. On the other hand, SBP had no significant association 
with serum uric acid levels in both sexes.
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Figure 2. The association between serum uric acid and systolic blood pressure at baseline 
in men fitted by B-spline methods
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Figure 3. The association between serum uric acid and systolic blood pressure at baseline 
in women fitted by B-spline methods
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Figure 4. The association between serum uric acid and diastolic blood pressure at baseline 
in men fitted by B-spline methods
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Figure 5. The association between serum uric acid and diastolic blood pressure at baseline 
in women fitted by B-spline methods
26
Table 6 shows the prospective association between serum uric acid level and incident 
hypertension using a generalized linear model. The unadjusted relative risk (95% CI) for 
incident hypertension in total participants was 1.18 (1.01-1.37) per 1.0 mg/dL increase in 
baseline serum uric acid (p=0.034). When adjusting for sex, age, BMI, SBP, DBP, HDL 
cholesterol and creatinine, relative risk (95% CI) was 1.19 per 1.0 mg/dL increase in 
baseline serum uric acid (p = 0.087). Stratified according to sex, relative risk (95% CI) 
were 1.20 (0.91-1.57) in men and 1.25 (0.93-1.69) in women after adjusting for age, BMI, 
SBP, DBP, HDL cholesterol and creatinine. 
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Table 6. Relative risk and associated 95% confidence interval of hypertension 
according to serum uric acid levels during follow-up period
Models
Relative risk (95% CI) for incident 
hypertension per serum uric acid 1.0 mg/dL 
p value
Total (n=808)
Unadjusted 1.18 (1.01 - 1.37) 0.034
Model 1 1.23 (0.94 - 1.33) 0.190
Model 2 1.14 (0.96 - 1.36) 0.137
Model 3 1.19 (0.98 - 1.44) 0.087
Men (n=314)
Unadjusted 1.21 (0.95 - 1.54) 0.126
Model 1 1.13 (0.90 - 1.42) 0.297
Model 2 1.15 (0.90 - 1.46) 0.255
Model 3 1.20 (0.91 - 1.57) 0.194
Women (n=494)
Unadjusted 1.24 (0.96 - 1.59) 0.093
Model 1 1.10 (0.85 - 1.43) 0.457
Model 2 1.12 (0.88 - 1.44) 0.360
Model 3 1.25 (0.93 - 1.69) 0.139
Model 1: adjusted for sex, age and BMI
Model 2: adjusted for sex, age, BMI, SBP and DBP
Model 3: adjusted for sex, age, BMI, SBP, DBP, HDL cholesterol and creatinine
Abbreviation: BMI, body mass index; CI, confidence interval; DBP, diastolic blood pressure;
HDL, high-density lipoprotein; SBP, systolic blood pressure
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Figure 6 presents relative risks for incident hypertension according to serum uric acid 
levels by restricted cubic spline. The relative risks were adjusted for age, BMI, baseline 
SBP, baseline DBP, HDL cholesterol and creatinine. Knots were set at the 5th, 25th, 75th, 
and 95th percentiles, and the plot was truncated at the 1st and 99th percentiles. The 
median to serum uric acid level was used as the reference. There was no significant 
association between serum uric acid and incident hypertension (p-value for the non-linear 
relation of 0.075; p-value for the linear relation of 0.120). 
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Figure 6. The association of serum uric acid levels with relative risks for incident 
hypertension, restricted cubic splines
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Table 7 shows associations between serum uric acid level and incident hypertension
among subgroups categorized by known risk factors for hypertension including sex, age, 
BMI, triglycerides, HDL cholesterol, LDL cholesterol and fasting glucose. The 
interaction test for sex was not significant (p interaction with sex = 0.936).
We found that an association between serum uric acid level and incident hypertension 
was significant in participants of age < 55 years (relative risk 1.74 per 1 mg/dL increase 
in serum uric acid, p = 0.002), but the association was not significant in participants of 
age ≥ 55 years (p = 0.894). In addition to, when analyzed people age ≥ 55 years divided 
into people who aged 55-64 years and ≥ 65 years, the associations between uric acid and 
incident diabetes among them were not different from people’s age ≥ 55 years (data not 
shown). The interaction test for age was significant (p interaction with age = 0.009). 
However, the p for interaction tests of BMI, triglycerides, HDL cholesterol, LDL 
cholesterol and fasting glucose was not significant.
Additionally, we examined whether smoking status modifies the association between 
serum uric acid level and incident hypertension (Table A2). Smoking status did not 
modify the association between serum uric acid level and incident hypertension, but 
reliability of the result is low due to the small number of samples.
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Table 7. Associations between serum uric acid and incident hypertension according to sex, age, body 
mass index, lipid profiles and fasting glucose using a generalized linear model*
Subgroup
No. of 
participants
No. of 
incident case
Relative risk (95% CI) p value
p
interaction†
Sex
Men 314 36 1.18 (0.90 - 1.55) 0.221 0.936
Women 494 53 1.20 (0.91 - 1.59) 0.196
Age
< 55 year 374 29 1.74 (1.22 - 2.47) 0.002 0.009
≥ 55 year 434 60 0.98 (0.77 - 1.25) 0.894
BMI
< 25 kg/m2 476 40 1.10 (0.78 - 1.53) 0.591 0.575
≥ 25 kg/m2 332 49 1.24 (0.97 - 1.58) 0.089
Triglycerides
< 150 mg/dL 524 48 1.20 (0.90 - 1.59) 0.215 0.826
≥ 150 mg/dL 284 41 1.14 (0.86 - 1.53) 0.366
HDL cholesterol 
≤ 40 mg/dL 272 46 1.12 (0.86 - 1.45) 0.391 0.395
> 40 mg/dL 536 43 1.33 (0.98 - 1.82) 0.067
LDL cholesterol
< 130 mg/dL 501 58 1.17 (0.93 - 1.46) 0.181 0.960
≥ 130 mg/dL 307 31 1.15 (0.76 - 1.74) 0.495
Fasting glucose
< 100 mg/dL 628 63 1.04 (0.82 - 1.33) 0.727 0.099
≥ 100 mg/dL 180 26 1.50 (1.05 - 2.13) 0.025
*Adjusted for sex, age, BMI, SBP, DBP, HDL cholesterol and creatinine
†The p value for interactions between serum uric acid and known risk factors on the risk of developing 
hypertension were calculated by a Z-test.
Abbreviation: BMI, body mass index; CI, confidence interval; DBP, diastolic blood pressure; HDL, 
high-density lipoprotein; LDL, low-density lipoprotein; SBP, systolic blood pressure
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Figure 7 shows relative risks for incident hypertension according to serum uric acid 
levels by participant’s age using restricted cubic spline. The relative risks were adjusted 
for age, BMI, baseline SBP, baseline DBP, HDL cholesterol and creatinine. Knots were 
set at the 5th, 25th, 75th, and 95th percentiles, and the plot was truncated at the 1st and 
99th percentiles. The median to serum uric acid level was used as the reference. In people 
who aged < 55 years, there was a significant linear association between serum uric acid 
and incident hypertension (p-value for the non-linear relation of 0.196; p-value for the 
linear relation of 0.002). Thus, we show the linear model. However, among people who 
aged ≥ 55 years, there was no significant linear association between serum uric acid and 
incident hypertension (p-value for the non-linear relation of 0.282; p-value for the linear 
relation of 0.909). 
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Age < 55 years
Age ≥ 55 years
Figure 7. The association of serum uric acid levels with relative risks for incident 
hypertension by participant’s age, restricted cubic splines
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IV. Discussion
We examined whether there is an independent association between serum uric acid 
and incident hypertension and assessed the interaction between serum uric acid and other 
risk factors for progression of blood pressure and incident hypertension. We observed that 
age-differential association between serum uric acid level and incident hypertension. The 
association between serum uric acid level and incident hypertension was positively 
significant among people who aged < 55 years, but there was no significant association 
among people who aged ≥ 55 years (p for interaction=0.009).
1. Associations of serum uric acid and other risk factors with incident 
hypertension in previous studies
A previous longitudinal study with a mean follow-up 5.41 years in a Taiwanese
population suggested that serum uric acid level was an independent predictor of incident 
hypertension32. The Beaver Dam Eye Study, which is a population-based cohort study 
with older Americans in Wisconsin, also observed that increasing quartiles of serum uric 
acid was associated with 10-year incidence of hypertension independent of smoking, 
alcohol intake and baseline kidney function33. Another longitudinal study over 8 years 
with Americans reported that higher baseline SBP and lower HDL cholesterol were
significant independent predictors for incident hypertension in a multivariate Cox 
regression model34
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In previous cross-sectional study in which investigate interaction of blood pressure 
and other risk factors on hypertension, the interaction between serum uric acid and 
triglyceride was significant for SBP, but not for DBP after adjusting for sex and age 35. 
Higher serum uric acid level was significantly associated with prehypertension in a group 
with triglycerides level of < 150 mg/dL, but not in a group with triglycerides level of ≥ 
150 mg/dL. Another study reported that there was an independent and positive 
association between serum acid and hypertension suggesting HDL cholesterol may 
modify the association between serum uric acid and hypertension36. In that study, the 
associations between uric acid and hypertension were most prominent in those with 
highest quintiles of HDL cholesterol. In the Physicians’ Health Study among men without 
diabetes and obesity, there was an independent association between baseline lipids (total 
cholesterol, HDL cholesterol and total cholesterol/HDL cholesterol ratio) and 
hypertension37. This previous study suggested that dyslipidemia may lead to the 
subsequent development of hypertension. The Women’s Health Study was also reported 
that dyslipidemia was independently associated with the subsequent development of 
hypertension among healthy women38. The Tehran Lipid and Glucose Study from a 
population-based cohort in the Middle East, suggested that dyslipidemia measured by 
serum triglycerides and triglycerides/HDL cholesterol ratio may be useful in 
identification of women at risk of hypertension39. However, the interactions of serum uric 
acid with lipid profiles on the blood pressure were not significant in the current study. 
Another previous longitudinal study with young and middle-aged Japanese male 
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reported that high serum uric acid level was also associated with future hypertension and 
this association was stronger in participants aged 40-60 years than that of those who aged 
18-40 years (p for interaction = 0.035)11. We observed that age-differential association 
between serum uric acid level and incident hypertension. The positive association was 
significant in participants of age < 55 years, but there was no significant association in 
participants of age ≥ 55 years. Considering these results, elevated serum uric acid level 
can be a trigger for hypertension in middle aged population.
2. Potential mechanisms linking the association of serum uric acid and other
risk factors for incident hypertension
The mechanism linking the association between increased serum uric acid level and 
incident hypertension is not completely understood. Previous studies reported that 
oxidative stress, inflammation, nitric oxide production impairment, vascular endothelial 
dysfunction, vascular smooth muscle proliferation, and renin angiotensin system 
enhancement were mechanisms for incident hypertension by hyperuricemia40-46. 
Crystallization of uric acid itself has also been reported to cause inflammation, gouty 
kidney, and urinary tract, and progression to renal failure47-50. High serum uric acid level 
may lead to decreasing of endothelial nitric oxide, which is well known as a mediator of 
insulin action and increases blood flow to skeletal muscle and enhance glucose uptake40. 
High serum uric acid can cause renal vasoconstriction and alters the 
proliferation/migration on endothelial and vascular smooth muscle cells through 
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inhibition of the nitric oxide and stimulation of the renin-angiotensin system, and then 
may lead to endothelial dysfunction41-43,51,52. Thus, hyperuricemia may lead to raised 
blood pressure. In addition to, serum uric acid is an indicator of systematic 
inflammation53 and associated with cardiovascular risk factors such as insulin resistance54, 
BMI, total cholesterol, HDL cholesterol, triglycerides and fasting glucose54-56. 
In additional analyses, we considered blood lipids as covariates for incident 
hypertension, although these variables including total cholesterol, LDL cholesterol and 
triglycerides were not influential in a generalized linear model (data not shown). 
Dyslipidemia may lead to impairment in endothelial function and resulting in defective 
vasoregulation57, increasing arterial stiffness58, decreasing compliance and renal 
microvascular disease. It has been reported that high triglyceride level may cause
endothelial dysfunction59, the loss of vasomotor reactivity60 and arterial stiffness61.
Previous reported that high triglyceride level is significantly associated with insulin 
resistance41 which may lead to incident hypertension by promoting renal tubular sodium 
reabsorption, stimulating sympathetic nervous system reactivity and the renin-angiotensin 
system36. Previous study with postmenopausal women in Japan reported that reductions 
of triglycerides and serum uric acid are synergistic factors of reduction in insulin 
resistance62.
High levels of cholesterol and low levels of HDL cholesterol are also toxic for 
endothelial cells and impair the nitric oxide production, release and later activity57, and 
these status can cause incident hypertension. Especially, high level of HDL cholesterol 
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stimulates nitric oxide production and has antithrombotic and antioxidant function63-65.
Normal functional HDL cholesterol has high levels of anti-oxidants and active anti-
oxidant proteins and enzymes with high anti-oxidant potential and has anti-inflammatory 
activity64. Several studies have reported its atheroprotective role as a key player in reverse 
cholesterol transport. HDL cholesterol carries cholesterol in the circulation and delivers it 
to the liver so that it can be either reutilized for assembly of very low-density lipoprotein 
or excreted as free cholesterol or bile acids64,66. However, when antioxidant and anti-
inflammatory functions of HDL cholesterol are overwhelmed by pathological processes, 
such as inflammation, HDL cholesterol is converted into a dysfunctional pro-
inflammatory particle67,68. Elevated serum uric acid level may promote cardio-protective
role of HDL cholesterol and the conversion process of HDL cholesterol to pro-
inflammatory factor through endothelial dysfunction and systematic inflammation, which 
may promote the progression of blood pressure.
Previous studies reported that both of serum uric acid and lipids can cause incident 
hypertension through endothelial dysfunction and systematic inflammation13,35,36,39,62.
According to our analysis, blood lipids at baseline were not independent predictors for 
future hypertension, but serum uric acid, BMI, SBP and DBP were independent predictors 
for future hypertension when fully adjusted (Table A3). The results suggested that such 
unfavorable pathophysiological process induced by serum uric acid might be greater than 
that of blood lipids.
A previous prospective study examined the association of serum uric acid with 
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development of hypertension and impaired fasting glucose or type 2 diabetes mellitus21. 
In this previous study, elevated serum uric acid level was significantly associated future 
hypertension and impaired fasting glucose or type 2 diabetes mellitus. In our study, 
fasting glucose level was not independent predictor for hypertension in generalized linear 
model (data not shown), but serum uric acid level was significantly associated with 
incident hypertension in a group with fasting glucose level of ≥ 100 mg/dL, (relative risk 
1.50 per 1 mg/dL, p=0.025) although the interaction with fasting glucose group was not 
significant (p for interaction with fasting glucose=0.099). It is suggesting that elevated 
serum uric acid might increase fasting glucose level through mechanisms linking 
decreasing of endothelial nitric oxide, which is above mentioned as a mediator of insulin 
action and increases blood flow to skeletal muscle and enhance glucose uptake40.
In our study, the association between serum uric acid and incident hypertension is 
inconsistent according to subgroups which were categorized by age. We cannot explain 
how age modifies the effects of uric acid on the development of hypertension. One of the 
possible explanations can be pathophysiological change with aging. If serum uric acid can 
affect premature vascular degeneration, serum uric acid could not affect elderly people 
whose pathophysiological changes including premature vascular degeneration and
endothelial dysfunction may have already been done with aging. The potential underlying 
mechanisms between uric acid and hypertension was very similar to a process of 
progression in blood pressure69. Thus, increased serum uric acid level can be a trigger for 
hypertension through early vascular change in middle aged population, but it cannot be 
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among people aged ≥ 55 years. A previous study suggested that uric acid level might have 
a role in the early pathogenesis of primary hypertension70,71. Furthermore, previous study 
reported that the strength of the relationship between uric acid and hypertension decreases 
with increasing patient age and duration of hypertension, suggesting that uric acid may be 
most important in younger people with early-onset hypertension72.
Another possible explanation is that serum uric acid is associated with an increase of 
DBP rather than SBP. Previous studies have reported that the prevalence of isolated 
systolic hypertension (SBP ≥ 160 and DBP < 95 or 90 mmHg) rise with age73-76. In these 
previous studies, SBP was increases with age at least until more than 80 years old, but 
DBP rises only until 50-60 years of age, and thereafter either levels off, or even slightly 
decreases. A study with Korean adults also reported similar results77. In this previous 
study, mean SBP increased progressively across entire age range. In contrast, mean DBP 
increased slightly before the age of 55 years, since then DBP plateaued or decreased. In 
the 2011 Korean National Health and Nutrition Examination Survey, SBP steadily 
increase with age more than 60 years whereas DBP decrease, resulting in an increase in 
the pulse pressure78. In our secondary analysis, serum uric acid level was not associated 
with an increase of SBP, but positively associated with an increase of DBP (Table A5). It 
is likely that higher serum uric acid is associated with an increase of DBP rather than SBP, 
but higher serum uric acid level could not affect participants aged ≥ 55 years as DBP 
level get closer to maximum in the age of ≥ 55 years. Therefore, the age-differential 
association between serum uric acid and incident hypertension in our study can be partly 
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explained that isolated systolic hypertension, which is predominates after the age of 50 
years as SBP continues to rise and DBP tends to fall, and results of our secondary analysis 
that serum uric acid level was significantly associated with only DBP. Further studies are 
needed to clarify interrelationships between serum uric acid and age for incident 
hypertension and which group is most vulnerable to incident hypertension. It is also 
needed to assess whether treatment strategies need to be targeted differentially according 
to each individual’s comorbid risk factor. 
3. Limitations of the current study
The current study has some limitations. First, it may not be appropriate to generalize 
it to another ethnic group because this study was conducted among Korean adults from a
single rural community. Second, we could not take into account day-to-day variation of 
blood pressure because blood pressure level was decided in a single visit, although we 
conducted blood pressure measurement multiple times. These may have led to a 
misclassification of incident hypertension. However, the effects of non-differential 
misclassification would have resulted in bias toward the null. Third, we did not consider 
medications for diabetes and dyslipidemia as covariates. Fasting glucose levels and blood 
lipids can be influenced these medications. Fourth, although even though we took into 
consideration a large number of potential confounders, the possibility remains that 
unmeasured factors such as specific dietary patterns could account for the association of 
serum uric acid with incident hypertension.
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V. Conclusions
We observed that age-differential association between serum uric acid level and 
incident hypertension among community-dwelling healthy Korean population. The 
positive association was significant among middle-aged population (< 55 years). Our 
study suggests that, to prevent future hypertension and cardiovascular disease effectively,
active intervention to avoid increasing serum uric acid level may be required, especially 
in middle-aged healthy population. 
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Appendix
Table A1. Correlation between blood pressure and other characteristics in baseline
SBP DBP
Pearson 
coefficients*
p-value
Pearson 
coefficients†
p-value
Pearson 
coefficients*
p-value
Pearson 
coefficients†
p-value
Total (n=808)
Age 0.20 <.001 NA NA - 0.04 0.261 NA NA
BMI 0.17 <.001 0.19 <.001 0.18 <.001 0.18 <.001
SBP NA NA NA NA 0.64 <.001 0.66 <.001
DBP 0.64 <.001 0.66 <.001 NA NA NA NA
Fasting glucose 0.09 0.009 0.09 0.011 0.03 0.330 0.04 0.319 
Fasting insulin 0.13 <.001 0.14 <.001 0.15 <.001 0.15 <.001
HOMA-IR 0.13 <.001 0.14 <.001 0.12 0.001 0.12 0.001 
Total cholesterol 0.08 0.018 0.09 0.012 0.07 0.046 0.07 0.048 
HDL cholesterol - 0.05 0.159 - 0.04 0.219 - 0.03 0.413 - 0.03 0.390 
LDL cholesterol <.01 0.958 0.01 0.852 - 0.03 0.371 - 0.03 0.357 
Triglycerides 0.22 <.001 0.22 <.001 0.23 <.001 0.24 <.001
Creatinine - 0.02 0.621 - 0.04 0.318 0.01 0.726 0.02 0.655 
GFR 0.01 0.824 0.15 <.001 0.11 0.001 0.11 0.002 
Uric acid 0.03 0.350 0.02 0.488 0.10 0.006 0.10 0.005
CRP 0.13 <.001 0.10 0.004 0.10 0.004 0.11 0.002 
Men (n=314)
Age 0.10 0.064 NA NA - 0.18 0.002 NA NA
BMI 0.20 <.001 0.23 <.001 0.22 <.001 0.19 0.001 
SBP NA NA NA NA 0.63 <.001 0.66 <.001
DBP 0.63 <.001 0.66 <.001 NA NA NA NA
Fasting glucose 0.04 0.428 0.06 0.309 0.06 0.257 0.04 0.431 
Fasting insulin 0.20 <.001 0.22 <.001 0.21 <.001 0.18 0.001 
HOMA-IR 0.15 0.007 0.17 0.002 0.15 0.007 0.13 0.024 
Total cholesterol 0.09 0.101 0.11 0.061 0.12 0.040 0.10 0.084 
HDL cholesterol <.01 1.000 <.01 0.956 0.01 0.855 0.02 0.780 
LDL cholesterol 0.01 0.822 0.02 0.727 - 0.02 0.772 -0.03 0.613 
Triglycerides 0.17 0.002 0.19 0.001 0.28 <.001 0.27 <.001
Creatinine - 0.07 0.230 - 0.07 0.190 - 0.02 0.787 -0.01 0.926 
GFR 0.10 0.065 0.21 0.000 0.22 <.001 0.14 0.012 
Uric acid 0.02 0.716 0.03 0.619 0.15 0.008 0.14 0.014 
CRP (L) 0.12 0.028 0.12 0.040 0.19 0.001 0.21 <.001
Women (n=494)
Age 0.26 <.001 NA NA 0.04 0.388 NA NA
BMI 0.15 0.001 0.15 0.001 0.16 <.001 0.16 <.001
SBP NA NA NA NA 0.64 <.001 0.65 <.001
DBP 0.64 <.001 0.65 <.001 NA NA NA NA
Fasting glucose 0.13 0.005 0.10 0.027 0.01 0.762 0.01 0.837 
Fasting insulin 0.08 0.080 0.08 0.075 0.11 0.017 0.11 0.017 
HOMA-IR 0.12 0.006 0.11 0.018 0.10 0.034 0.09 0.040 
Total cholesterol 0.08 0.082 0.07 0.123 0.04 0.332 0.04 0.351 
HDL cholesterol - 0.08 0.088 - 0.06 0.179 -0.05 0.258 -0.05 0.284 
LDL cholesterol <.01 0.921 - 0.01 0.904 -0.04 0.369 -0.04 0.368 
Triglycerides 0.25 <.001 0.22 <.001 0.20 <.001 0.20 <.001
Creatinine 0.02 0.670 - 0.01 0.857 0.03 0.461 0.03 0.515 
GFR - 0.05 0.264 0.10 0.023 0.05 0.296 0.08 0.079 
Uric acid 0.04 0.344 0.01 0.837 0.06 0.199 0.05 0.238 
CRP 0.13 0.004 0.09 0.046 0.05 0.248 0.05 0.306 
*Adjusted for sex; †Adjusted for sex and age 
Abbreviation: BMI, body mass index; CRP, C-reactive protein; DBP, diastolic blood pressure; GFR, glomerular filtration 
ratio; HDL, high-density lipoprotein; HOMA-IR, homeostatic model assessment for insulin resistance; LDL, low-density 
lipoprotein; SBP, systolic blood pressure
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Table A2. Associations between serum uric acid and incident hypertension by smoking status
No. of 
people
No. of incident 
case
RR (95% CI) p value p interaction
Smoking status
  Current smoker 81 10 1.53 (0.86 - 2.74) 0.150 0.363
  Non-smoker 697 77 1.15 (0.92 - 1.43) 0.220
*Adjusted for sex, age, BMI, SBP, DBP, HDL cholesterol and creatinine
Abbreviation: BMI, body mass index; CI, confidence interval; DBP, diastolic blood pressure; HDL, high-
density lipoprotein; SBP, systolic blood pressure; RR, relative risk
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Table A3. Adjusted relative risk and associated 95% confidential interval for indent 
hypertension using a generalized linear model*
Variables Relative risk (95% CI) p value
Total (n=808)
Uric acid, mg/dL 1.19 (0.98 - 1.44) 0.087 
Sex, men 1.27 (0.72 - 2.23) 0.405 
Age, year 1.04 (1.01 - 1.08) 0.008 
BMI, kg/m2 1.07 (1.00 - 1.14) 0.043 
SBP, mmHg 1.04 (1.02 - 1.07) <.001
DBP, mmHg 1.04 (1.00 - 1.08) 0.035 
HDL cholesterol, mg/dL 0.98 (0.96 - 1.01) 0.162 
Creatinine, mg/dL 0.32 (0.05 - 2.17) 0.243 
Men (n=314)
Uric acid, mg/dL 1.20 (0.91 - 1.59) 0.196 
Age, year 1.05 (1.01 - 1.09) 0.021 
BMI, kg/m2 1.05 (0.96 - 1.14) 0.285 
SBP, mmHg 1.05 (1.02 - 1.09) 0.001 
DBP, mmHg 1.05 (1.00 - 1.10) 0.044 
HDL cholesterol, mg/dL 0.98 (0.96 - 1.01) 0.259 
Creatinine, mg/dL 0.22 (0.02 - 3.02) 0.258 
Women (n=494)
Uric acid, mg/dL 1.18 (0.90 - 1.55) 0.221 
Age, year 1.04 (0.98 - 1.10) 0.163 
BMI, kg/m2 1.12 (1.00 - 1.25) 0.046 
SBP, mmHg 1.03 (0.99 - 1.07) 0.147 
DBP, mmHg 1.03 (0.96 - 1.09) 0.409 
HDL cholesterol, mg/dL 0.99 (0.95 - 1.02) 0.476 
Creatinine, mg/dL 0.36 (0.02 - 6.12) 0.482 
*Adjusted for all variables in the tables
Abbreviation: BMI, body mass index; DBP, diastolic blood pressure; HDL, high-density lipoprotein; 
SBP, systolic blood pressure
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Table A4. Baseline characteristics of study participants according to age
Variables
Participants of age < 55 
years (n=374)
Participants of age ≥ 55 
years (n=434)
p-value
Sex, men 107 (28.6) 207 (47.7) <.001
Age, years 48.9 ± 3.6 61.0 ± 4.3 <.001
BMI, kg/m2 24.7 ± 3.1 24.3 ± 3.1 0.038 
SBP, mmHg 113.5 ± 11.8 118.3 ± 12.2 <.001
DBP, mmHg 71.6 ± 8.9 72.3 ± 7.9 0.234 
Fasting glucose, mg/dL 91.0 [85.0-97.0] 92.0 [86.0-99.0] 0.194 
Fasting insulin, mg/dL 7.8 [6.1-10.6] 7.5 [5.9-10.0] 0.054 
HOMA-IR 2.0 ± 0.9 2.0 ± 1.1 0.794 
Total cholesterol, mg/dL 196.8 ± 33.5 194.5 ± 35.3 0.348 
HDL cholesterol,mg/dL 46.2 ± 10.8 44.9 ± 10.7 0.089 
LDL cholesterol,mg/dL 123.2 ± 31.2 120.5 ± 33.6 0.230 
Triglycerides, mg/dL 118.5 [84.0-164.0] 126.5 [88.0-178.0] 0.049 
Uric acid, mg/dL 4.8 ± 1.2 5.1 ± 1.3 <.001
Creatinine, mg/dL 0.9 ± 0.1 0.9 ± 0.2 <.001
GFR, mL/min/1.73m2 78.8 ± 14.2 66.4 ± 13.9 <.001
C-reactive protein, mg/L 0.6 [0.3-1.2] 0.7 [0.4-1.5] <.001
Current smoker 37 (10.3) 44 (10.5) 1.000 
Current drinker 153 (41.1) 157 (36.2) 0.171 
p-value was derived from the independent t-test, the Wilcoxon rank sum test or chi-square test
Abbreviation: BMI, body mass index; CRP, C-reactive protein; DBP, diastolic blood pressure; GFR, 
glomerular filtration ratio; HDL, high-density lipoprotein; HOMA-IR, homeostatic model assessment 
for insulin resistance; L, logarithmic; LDL, low-density lipoprotein; SBP, systolic blood pressure
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Table A5. Adjusted relative risk and associated 95% confidential interval for indent 
hypertension according to age using a generalized linear model*
Variables Relative risk (95% CI) p value
Age < 55
Serum uric acid, mg/dL 1.74 (1.22 - 2.47) 0.002 
Sex, men 2.19 (0.71 - 6.75) 0.174 
Age, year 1.05 (0.94 - 1.18) 0.376 
BMI, kg/m2 1.03 (0.92 - 1.15) 0.597 
SBP, mmHg 1.05 (1.00 - 1.11) 0.041 
DBP, mmHg 1.08 (1.00 - 1.16) 0.045 
HDL cholesterol, mg/dL 0.98 (0.94 - 1.03) 0.444 
Creatinine, mg/dL 0.22 (0.01 - 7.25) 0.397 
Age ≥ 55
Serum uric acid, mg/dL 0.98 (0.77 - 1.25) 0.894 
Sex, men 1.03 (0.53 - 2.01) 0.932 
Age, year 1.06 (1.00 - 1.13) 0.064 
BMI, kg/m2 1.08 (1.00 - 1.17) 0.065 
SBP, mmHg 1.04 (1.01 - 1.07) 0.005 
DBP, mmHg 1.02 (0.98 - 1.06) 0.396 
HDL cholesterol, mg/dL 0.98 (0.96 - 1.01) 0.253 
Creatinine, mg/dL 0.40 (0.04 - 4.17) 0.445 
Abbreviation: BMI, body mass index; CI, confidence interval; CRP, C-reactive protein; DBP, 
diastolic blood pressure; HOMA-IR, homeostatic model assessment for insulin resistance; SBP, 
systolic blood pressure
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Table A6. Relative risk and 95% confidence interval of increasing systolic and diastolic blood pressure according to 
serum uric acid levels during follow-up period
20mmHg increase of SBP
per serum uric acid 1.0 mg/dL
10mmHg increase of DBP
per serum uric acid 1.0 mg/dL
Models
No. of 
case
Relative risk (95% CI) p value
No. of 
case
Relative risk (95% CI) p value
Total (n=808) 37 123
Unadjusted 1.23 (0.98 - 1.55) 0.071 1.18 (1.04 - 1.34) 0.011
Adjusted 1.22 (0.90 - 1.64) 0.196 1.29 (1.09 - 1.53) 0.003
Men (n=314) 16 48
Unadjusted 1.18 (0.81 - 1.70) 0.385 1.11 (0.89 - 1.38) 0.360
Adjusted 1.12 (0.74 - 1.68) 0.598 1.08 (0.85 - 1.38) 0.507
Women (n=494) 21 75
Unadjusted 1.38 (0.94 - 2.02) 0.101 1.39 (1.14 - 1.71) 0.001
Adjusted 1.24 (0.79 - 1.94) 0.359 1.51 (1.19 - 1.91) 0.001
*Adjusted for sex, age, BMI, SBP, DBP, HDL cholesterol and creatinine 
Abbreviation: BMI, body mass index; CI, confidence interval; DBP, diastolic blood pressure; HDL, high-density 
lipoprotein; SBP, systolic blood pressure
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Figure A1. The association between serum uric acid and systolic blood pressure at baseline 
among people < 55 years old fitted by B-spline methods
61
Figure A2. The association between serum uric acid and systolic blood pressure at baseline 
among people ≥ 55 years old fitted by B-spline methods
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Figure A3. The association between uric acid and diastolic blood pressure at baseline 
among people < 55 years old fitted by B-spline methods
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Figure A4. The association between uric acid and diastolic blood pressure at baseline 
among people ≥ 55 years old fitted by B-spline methods
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ABSTRACT (In Korean)
연령에 따른 혈중 요산과 고혈압 발생의 관련성
<지도교수 김현창>
연세대학교 대학원 보건학과
이승원
서론: 여러 선행연구들에서 높은 혈중 요산 수치가 고혈압 발생 위험 증가와
관련이 있었다. 그러나 혈중 요산 농도와 고혈압 발생의 관련성은 연령이나
성별, 혈중 지질, 비만도 등에 따라 달라지기도 하였다. 본 연구에서는 건강한
한국인을 대상으로 고혈압 발생에 대한 혈중 요산 농도의 관련성을 조사하고, 
잘 알려진 고혈압 관련 위험요인에 의해 그 관련성이 달라지는지 알아보고자
하였다.
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방법: 이 연구는 지역사회에 기반한 전향적 코호트 연구인 Korean Genome 
Epidemiology Study (KoGES-Kangwha)에 참여한 사람들 중 베이스라인에서
고혈압과 주요 심혈관 질환 과거력이 없었던 808명(40-79세)을 대상으로 하였
다. 고혈압은 수축기 혈압이 140mmHg 이상, 이완기 혈압이 90mmHg 이상이
거나, 항고혈압 약제 복용으로 정의하였다. 기반조사에서 혈중 요산 농도와 혈
압의 단면적인 관련성을 알아보기 위하여 다중 선형회귀분석을 사용하였다.
공변량은 성별, 연령, 체질량지수, 고밀도지단백 콜레스테롤, 크레아티닌이었
다. 혈중 요산 수준에 따른 고혈압 발생의 비교위험도를 구하기 위해 일반화
선형 모형을 사용하였고, 요산 농도와 고혈압 발생의 관련성이 관련 위험요인
에 의해 달라지는지 알아보기 위해, 성별과 연령(<55, ≥55세), 체질량지수(<25, 
≥25kg/m2), 중성지방(<150, ≥150mg/dL), 고밀도지단백 콜레스테롤(40≤, 
>40mg/dL), 저밀도지단백 콜레스테롤(130≤, >130mg/dL), 공복혈당(110≤, 
>110mg/dL)에 따라 그룹을 나누어 z-test를 실시하였다. 
결과: 본 연구에는 중년의 남자 314명과 여자 494명을 포함하였다. 평균 3.3
년의 추적조사 기간 동안 고혈압이 발생한 사람은 남자 36명(11.5%)과 여자
53명(10.7%)이었다. 기반조사에서의 단면적 관련성을 분석했을 때, 혈중 요산
농도는 성별, 연령, 체질량지수, 고밀도지단백 콜레스테롤, 크레아티닌을 보정
했을 때 남자에서만 이완기혈압과 양의 관련성이 있었다. 종적인 관련성을 보
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았을 때는 대상자의 연령에 따라 혈중 요산 농도와 고혈압 발생의 관련성이
달라졌다(p for interaction=0.009). 연령이 55세 이상인 그룹에서는 혈중 요산
농도와 고혈압 발생이 유의한 관련성을 보이지 않았지만, 55세 미만에서는 유
의한 관련성을 보였다(혈중 요산 농도 1.0 mg/dL 증가 당 비교위험도 1.74, 
p=0.002). 그러나 체질량지수, 중성지방, 공복혈당, 고밀도지단백 콜레스테롤,
저밀도지단백 콜레스테롤은 혈중 요산과 고혈압 발생의 관련성에 영향을 주지
못하였다.
고찰: 본 연구에서는 연령에 따라 혈중 요산 농도와 향후 고혈압 발생의 관련
성이 다름을 확인하였다. 55세 이상인 사람들에서는 혈중 요산 농도와 고혈압
발생이 유의한 관련성이 없었지만, 55세 미만인 사람들에서는 높은 혈중 요산
농도가 고혈압 발생의 위험을 증가시키는 것으로 나타났다. 중년의 성인에서
고혈압 예방과 고위험군 선별을 위해서는 혈중 요산 농도의 측정과 관리가 도
움이 될 것이다.
핵심 되는 말: 고혈압, 혈압, 혈중 요산, 교호작용, 위험요인, 연령
